RNXT - Kewajiban jangka dawa perusahaan RenovoRx Inc

Logo perusahaan publik RenovoRx Corp (RNXT)

The daily price chart for RenovoRx, Inc. (RNXT) is accompanied by compliance with environmental standards for polymer disposal. Business revenues will be based on the market launch of Renovo-Cath for precise drug delivery into tumors, where the metric is 0.00. RenovoRx, Inc. (RNXT) technology, RenovoTAMP, minimizes toxic impact on the body, significantly increasing chemotherapy effectiveness through localized drug delivery.

Utang jangka dawa perusahaan renovorx.com (RNXT): kanggo periode 04.07.2022 - 31.10.2026

Ringkesan rincian data analitis RenovoRx Corp (RNXT)

- rega saham lan prakiraan rega para ahli:
Kurs saham renovorx.com|RNXT - Prakiraan konsensus analis
- statistik kapitalisasi pasar:
Biji pasar RenovoRx|RNXT - Nilai Perusahaan
- data nilai buku modal saham:
Nilai Aset Bersih saben Saham RenovoRx|RNXT - Nilai Buku Perusahaan|Nilai Pasar marang Nilai Buku renovorx.com|RNXT - Gunggung Aset Perusahaan
- rincian struktur utang lan likuiditas bisnis:
Rasio Kabeh Utang marang Dana Pribadi RenovoRx, Inc.|RNXT - Utang jangka dawa marang ekuitas|Koefisien utang jangka cendhak marang modal RenovoRx Corporation|RNXT - Gunggung utang perusahaan|Utang marang modal buku RenovoRx|RNXT - Utang jangka dawa perusahaan|Utang jangka cendhak RenovoRx|Indikator likuiditas cepet renovorx.com
- rincian bathi lan kelipatan pasar:
RNXT - Bathi resik
Pambiji fundamental perusahaan:renovorx.com RNXT
Produk merek RenovoRx, Inc.

This indicator aggregates total liabilities with maturities exceeding one year, allowing for an assessment of the debt load and capital resilience against macroeconomic shocks. By analyzing the history of the firm's long-term borrowings, an investor can identify default risks for RenovoRx, Inc. (RNXT), whose early-stage clinical trials and lack of revenue make the company critically dependent on external financing as liquidity depletes.

Pesaing RenovoRx, Inc. (RNXT)

TLSI: Tanggungan utang jangka dawa perusahaan|PharmaCyte - Utang jangka dawa perusahaan